LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 82

Search options

  1. Article ; Online: Disseminated mucocutaneous leishmaniasis in a traveller with idiopathic CD4 lymphocytopenia.

    Thizy, Guillaume / Caumes, Eric / Molher, Joffrey / Ariey, Frederic / Lortholary, Olivier / Buffet, Pierre / Melenotte, Cléa

    Journal of travel medicine

    2023  Volume 30, Issue 8

    MeSH term(s) Humans ; Leishmaniasis, Mucocutaneous/diagnosis ; Leishmaniasis, Mucocutaneous/drug therapy ; Immunologic Deficiency Syndromes ; Thymus Gland ; Lymphopenia
    Language English
    Publishing date 2023-05-08
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1212504-0
    ISSN 1708-8305 ; 1195-1982
    ISSN (online) 1708-8305
    ISSN 1195-1982
    DOI 10.1093/jtm/taad063
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Conduite à tenir devant une morsure ou une griffure animale.

    Melenotte, Cléa / Lagier, Jean-Christophe

    La Revue du praticien

    2019  Volume 69, Issue 3, Page(s) 324–327

    Title translation Management of an c or scratch.
    Language French
    Publishing date 2019-05-17
    Publishing country France
    Document type Journal Article
    ZDB-ID 205365-2
    ISSN 2101-017X ; 0035-2640
    ISSN (online) 2101-017X
    ISSN 0035-2640
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Successful Rezafungin Treatment of an Azole-Resistant Chronic Mucocutaneous Candidiasis in a STAT-1 Gain-of-Function Patient.

    Melenotte, Cléa / Ratiney, Robert / Hermine, Olivier / Bougnoux, Marie-Elisabeth / Lanternier, Fanny

    Journal of clinical immunology

    2023  Volume 43, Issue 6, Page(s) 1182–1184

    MeSH term(s) Humans ; Azoles/pharmacology ; Azoles/therapeutic use ; Candidiasis, Chronic Mucocutaneous/drug therapy ; Candidiasis, Chronic Mucocutaneous/genetics ; Gain of Function Mutation ; Echinocandins ; Antifungal Agents/therapeutic use
    Chemical Substances Rezafungin (G013B5478J) ; Azoles ; Echinocandins ; Antifungal Agents
    Language English
    Publishing date 2023-05-29
    Publishing country Netherlands
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 779361-3
    ISSN 1573-2592 ; 0271-9142
    ISSN (online) 1573-2592
    ISSN 0271-9142
    DOI 10.1007/s10875-023-01519-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Pro-apoptotic effect of doxycycline and hydroxychloroquine on B-cell lymphoma induced by

    Melenotte, Cléa / Raoult, Didier

    Oncotarget

    2018  Volume 9, Issue 2, Page(s) 2726–2727

    Language English
    Publishing date 2018-01-05
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2560162-3
    ISSN 1949-2553 ; 1949-2553
    ISSN (online) 1949-2553
    ISSN 1949-2553
    DOI 10.18632/oncotarget.23397
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Author Correction: The immuno-oncological challenge of COVID-19.

    Derosa, Lisa / Melenotte, Cléa / Griscelli, Franck / Gachot, Bertrand / Marabelle, Aurélien / Kroemer, Guido / Zitvogel, Laurence

    Nature cancer

    2022  Volume 3, Issue 3, Page(s) 371

    Language English
    Publishing date 2022-02-08
    Publishing country England
    Document type Published Erratum
    ISSN 2662-1347
    ISSN (online) 2662-1347
    DOI 10.1038/s43018-022-00342-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Surge in Imported Cutaneous Leishmaniasis Cases from Mexico in 2023: A Case Series.

    Equihua Martinez, Gabriela / Del Moreno Castillo, Maria Cristina / Lindner, Andreas K / Gargala, Gilles / Cessot, Gilles / van de Werve, Charlotte / Caumes, Eric / Harms, Gundel / Aurbach, Ute / Kampmann, Beate / Buffet, Pierre / Melenotte, Cléa

    Journal of travel medicine

    2024  

    Abstract: In Europe, American cutaneous leishmaniasis caused by Leishmania mexicana is a rare imported disease. A series of six cases in 2023 is a noteworthy escalation at our institutions compared to the past two decades. This surge is likely linked to an ... ...

    Abstract In Europe, American cutaneous leishmaniasis caused by Leishmania mexicana is a rare imported disease. A series of six cases in 2023 is a noteworthy escalation at our institutions compared to the past two decades. This surge is likely linked to an increase of cases and environmental changes in South-Eastern Mexico.
    Language English
    Publishing date 2024-04-05
    Publishing country England
    Document type Journal Article
    ZDB-ID 1212504-0
    ISSN 1708-8305 ; 1195-1982
    ISSN (online) 1708-8305
    ISSN 1195-1982
    DOI 10.1093/jtm/taae051
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: New insights in

    Melenotte, Cléa / Million, Matthieu / Raoult, Didier

    Expert review of anti-infective therapy

    2019  Volume 18, Issue 1, Page(s) 75–86

    Abstract: ... ...

    Abstract Introduction
    MeSH term(s) Animals ; Antibodies, Anticardiolipin/blood ; Coxiella burnetii/isolation & purification ; Echocardiography ; Fluorodeoxyglucose F18 ; Humans ; Lymphoma, Non-Hodgkin/etiology ; Positron Emission Tomography Computed Tomography ; Q Fever/complications ; Q Fever/diagnosis ; Q Fever/microbiology ; Q Fever/therapy
    Chemical Substances Antibodies, Anticardiolipin ; Fluorodeoxyglucose F18 (0Z5B2CJX4D)
    Language English
    Publishing date 2019-12-06
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2181279-2
    ISSN 1744-8336 ; 1478-7210
    ISSN (online) 1744-8336
    ISSN 1478-7210
    DOI 10.1080/14787210.2020.1699055
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Could β-Lactam Antibiotics Block Humoral Immunity?

    Melenotte, Cléa / Pontarotti, Pierre / Pinault, Lucile / Mège, Jean-Louis / Devaux, Christian / Raoult, Didier

    Frontiers in immunology

    2021  Volume 12, Page(s) 680146

    Abstract: It has been reported that treatment with β-lactam antibiotics induces leukopenia and candidemia, worsens the clinical response to anticancer immunotherapy and decreases immune response to vaccination. β-lactamases can cleave β-lactam antibiotics by ... ...

    Abstract It has been reported that treatment with β-lactam antibiotics induces leukopenia and candidemia, worsens the clinical response to anticancer immunotherapy and decreases immune response to vaccination. β-lactamases can cleave β-lactam antibiotics by blocking their activity. Two distincts superfamilies of β-lactamases are described, the serine β-lactamases and the zinc ion dependent metallo-β-lactamases. In human, 18 metallo-β-lactamases encoding genes (hMBLs) have been identified. While the physiological role of most of them remains unknown, it is well established that the SNM1A, B and C proteins are involved in DNA repair. The SNM1C/Artemis protein is precisely associated in the V(D)J segments rearrangement, that leads to immunoglobulin (Ig) and T-cell receptor variable regions, which have a crucial role in the immune response. Thus in humans, SNM1C/Artemis mutation is associated with severe combined immunodeficiency characterized by hypogammaglobulinemia deficient cellular immunity and opportunistic infections. While catalytic site of hMBLs and especially that of the SNM1 family is highly conserved
    MeSH term(s) Animals ; Anti-Bacterial Agents/chemistry ; Anti-Bacterial Agents/pharmacology ; Binding Sites ; Catalysis ; DNA-Binding Proteins/chemistry ; DNA-Binding Proteins/metabolism ; Endonucleases/chemistry ; Endonucleases/metabolism ; Exodeoxyribonucleases/chemistry ; Exodeoxyribonucleases/metabolism ; Humans ; Immunity, Humoral/drug effects ; Immunosuppressive Agents/chemistry ; Immunosuppressive Agents/pharmacology ; Mutation ; Protein Binding ; beta-Lactams/chemistry ; beta-Lactams/pharmacology
    Chemical Substances Anti-Bacterial Agents ; DNA-Binding Proteins ; Immunosuppressive Agents ; beta-Lactams ; DCLRE1C protein, human (EC 3.1.-) ; Endonucleases (EC 3.1.-) ; Exodeoxyribonucleases (EC 3.1.-)
    Language English
    Publishing date 2021-09-15
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2021.680146
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19?

    Devaux, Christian A / Melenotte, Cléa / Piercecchi-Marti, Marie-Dominique / Delteil, Clémence / Raoult, Didier

    Frontiers in medicine

    2021  Volume 8, Page(s) 663708

    Abstract: Coronavirus disease 2019 (COVID-19) is now at the forefront of major health challenge faced globally, creating an urgent need for safe and efficient therapeutic strategies. Given the high attrition rates, high costs, and quite slow development of drug ... ...

    Abstract Coronavirus disease 2019 (COVID-19) is now at the forefront of major health challenge faced globally, creating an urgent need for safe and efficient therapeutic strategies. Given the high attrition rates, high costs, and quite slow development of drug discovery, repurposing of known FDA-approved molecules is increasingly becoming an attractive issue in order to quickly find molecules capable of preventing and/or curing COVID-19 patients. Cyclosporin A (CsA), a common anti-rejection drug widely used in transplantation, has recently been shown to exhibit substantial anti-SARS-CoV-2 antiviral activity and anti-COVID-19 effect. Here, we review the molecular mechanisms of action of CsA in order to highlight why this molecule seems to be an interesting candidate for the therapeutic management of COVID-19 patients. We conclude that CsA could have at least three major targets in COVID-19 patients: (i) an anti-inflammatory effect reducing the production of proinflammatory cytokines, (ii) an antiviral effect preventing the formation of the viral RNA synthesis complex, and (iii) an effect on tissue damage and thrombosis by acting against the deleterious action of angiotensin II. Several preliminary CsA clinical trials performed on COVID-19 patients report lower incidence of death and suggest that this strategy should be investigated further in order to assess in which context the benefit/risk ratio of repurposing CsA as first-line therapy in COVID-19 is the most favorable.
    Language English
    Publishing date 2021-09-06
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2775999-4
    ISSN 2296-858X
    ISSN 2296-858X
    DOI 10.3389/fmed.2021.663708
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Cyclosporin A

    Christian A. Devaux / Cléa Melenotte / Marie-Dominique Piercecchi-Marti / Clémence Delteil / Didier Raoult

    Frontiers in Medicine, Vol

    A Repurposable Drug in the Treatment of COVID-19?

    2021  Volume 8

    Abstract: Coronavirus disease 2019 (COVID-19) is now at the forefront of major health challenge faced globally, creating an urgent need for safe and efficient therapeutic strategies. Given the high attrition rates, high costs, and quite slow development of drug ... ...

    Abstract Coronavirus disease 2019 (COVID-19) is now at the forefront of major health challenge faced globally, creating an urgent need for safe and efficient therapeutic strategies. Given the high attrition rates, high costs, and quite slow development of drug discovery, repurposing of known FDA-approved molecules is increasingly becoming an attractive issue in order to quickly find molecules capable of preventing and/or curing COVID-19 patients. Cyclosporin A (CsA), a common anti-rejection drug widely used in transplantation, has recently been shown to exhibit substantial anti-SARS-CoV-2 antiviral activity and anti-COVID-19 effect. Here, we review the molecular mechanisms of action of CsA in order to highlight why this molecule seems to be an interesting candidate for the therapeutic management of COVID-19 patients. We conclude that CsA could have at least three major targets in COVID-19 patients: (i) an anti-inflammatory effect reducing the production of proinflammatory cytokines, (ii) an antiviral effect preventing the formation of the viral RNA synthesis complex, and (iii) an effect on tissue damage and thrombosis by acting against the deleterious action of angiotensin II. Several preliminary CsA clinical trials performed on COVID-19 patients report lower incidence of death and suggest that this strategy should be investigated further in order to assess in which context the benefit/risk ratio of repurposing CsA as first-line therapy in COVID-19 is the most favorable.
    Keywords SARS-CoV-2 ; COVID-19 ; cyclosporin A ; cyclophilin ; angiotensin converting enzyme-2 ; Medicine (General) ; R5-920
    Subject code 610
    Language English
    Publishing date 2021-09-01T00:00:00Z
    Publisher Frontiers Media S.A.
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top